Carcinoma, Adenoid Cystic - 25 Studies Found
Completed |
: Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) : Adenoid Cystic Carcinoma : 2016-01-22 : Drug: Brontictuzumab 1.5 mg/Kg intravenously every three weeks. |
Active, not recruiting |
: Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2014-03-24 : Drug: Regorafenib All eligible patients will receive a starting regorafenib dose of 120 mg daily taken o |
Completed |
: Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2012-03-16 : Drug: AG-013736 (AXITINIB) All eligible patients will receive a starting axitinib dose of 5 mg twice dai |
Recruiting |
: A Study of Apatinib in Metastatic Adenoid Cystic Carcinoma of the Head and Neck : Adenoid Cystic Carcinoma : 2016-05-12 : Drug: Apatinib Mesylate Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecu |
Not yet recruiting |
: Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2016-10-18 :
|
Active, not recruiting |
: Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 : Adenoid Cystic Carcinomas of the Salivary Glands : 2016-08-02 : Drug: Lenvatinib Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 |
Completed |
: A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands :
: 2009-04-20 : Drug: Sunitinib 37.5 mg taken orally, daily every 28-day cycles |
Completed |
: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands :
|
Recruiting |
: Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma : Recurrent ACC, metastaticACC, Unreaectable ACC : 2016-07-28 :
|
Completed |
: Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck : Head and Neck Cancer : 2001-06-06 : Drug: gemcitabine hydrochloride |